Elevated arteriolar cerebral blood volume in prodromal Huntington's disease

Movement Disorders

Volumn 29, Issue 3, 2014, Pages 396-401

  Hua, Jun ^a,b   Unschuld, Paul G ^d   Margolis, Russell L ^c   Van Zijl, Peter C M ^a,b   Ross, Christopher A ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Atrophy; Biomarker; Imaging; Neurodegeneration; Neurovascular

Indexed keywords

ADULT; ARTERIOLAR CEREBRAL BLOOD VOLUME; ARTICLE; BLOOD VOLUME; BRAIN ATROPHY; BRAIN CIRCULATION; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECT SIZE; FEMALE; FOLLOW UP; FRONTAL CORTEX; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PARIETAL CORTEX; PILOT STUDY; PRIORITY JOURNAL; PRODROMAL SYMPTOM; TEMPORAL CORTEX; AGED; ATROPHY; BLOOD; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

BIOLOGICAL MARKER;

ADULT; AGED; ATROPHY; BIOLOGICAL MARKERS; BLOOD VOLUME; FEMALE; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 84896111994     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25591     Document Type: Article

References (40)

1. Paulsen JS, Nopoulos PC, Aylward E, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010;82(3-4):201-207.
2. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-42.
3. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11:42-53.
4. Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011;82:405-410.
5. Zimbelman JL, Paulsen JS, Mikos A, Reynolds NC, Hoffmann RG, Rao SM. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc 2007;13:758-769.
6. Wolf RC, Sambataro F, Vasic N, et al. Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease. Exp Neurol 2011;231:214-222.
7. Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006;47:215-222.
8. Feigin A, Leenders KL, Moeller JR, et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med 2001;42:1591-1595.
9. Kuwert T, Noth J, Scholz D, et al. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease. Mov Disord 1993;8:98-106.
10. Sax DS, Powsner R, Kim A, et al. Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography. Mov Disord 1996;11:671-677.
11. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119(pt 6):2085-2095.
12. Powers WJ, Videen TO, Markham J, et al. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc Natl Acad Sci U S A 2007;104:2945-2949.
13. Cepeda-Prado E, Popp S, Khan U, et al. R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures. J Neurosci 2012;32:6456-6467.
14. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009;32:548-557.
15. Ma Y, Eidelberg D. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging Biol 2007;9:223-233.
16. Deckel AW, Weiner R, Szigeti D, Clark V, Vento J. Altered patterns of regional cerebral blood flow in patients with Huntington's disease: a SPECT study during rest and cognitive or motor activation. J Nucl Med 2000;41:773-780.
17. Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999;122(pt 9):1667-1678.
18. Wolf RC, Gron G, Sambataro F, et al. Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. J Cereb Blood Flow Metab 2011;31:1908-1918.
19. Chen JJ, Salat DH, Rosas HD. Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease. Neuroimage 2012;59:1043-1051.
20. Franciosi S, Ryu JK, Shim Y, et al. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2012;45:438-449.
21. Lin C, Huang C, Lin M, et al. Magnetic resonance microscopic angiography visualization of abnormal microvasculature in a transgenic mouse model of Huntington's disease. In: Proceedings of the ISMRM 18th Scientific Meeting and Exhibition; May 1-7, 2010; Stockholm, Sweden.
22. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 2007;10:1369-1376.
23. Ito H, Ibaraki M, Kanno I, Fukuda H, Miura S. Changes in the arterial fraction of human cerebral blood volume during hypercapnia and hypocapnia measured by positron emission tomography. J Cereb Blood Flow Metab 2005;25:852-857.
24. Kim T, Hendrich KS, Masamoto K, Kim SG. Arterial versus total blood volume changes during neural activity-induced cerebral blood flow change: implication for BOLD fMRI. J Cereb Blood Flow Metab 2007;27:1235-1247.
25. Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, Nedergaard M. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 2006;9:260-267.
26. Hua J, Qin Q, Donahue MJ, Zhou J, Pekar JJ, van Zijl PC. Inflow-based vascular-space-occupancy (iVASO) MRI. Magn Reson Med 2011;66:40-56.
27. Hua J, Qin Q, Pekar JJ, Zijl PC. Measurement of absolute arterial cerebral blood volume in human brain without using a contrast agent. NMR Biomed 2011;24:1313-1325.
28. Donahue MJ, Sideso E, MacIntosh BJ, Kennedy J, Handa A, Jezzard P. Absolute arterial cerebral blood volume quantification using inflow vascular-space-occupancy with dynamic subtraction magnetic resonance imaging. J Cereb Blood Flow Metab 2010;30:1329-1342.
29. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005;234:851-859.
30. Bazin PL, Pham DL. Topology-preserving tissue classification of magnetic resonance brain images. IEEE Trans Med Imaging 2007;26:487-496.
31. Zhang Y, Long JD, Mills JA, Warner JH, Lu W, Paulsen JS. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet 2011;156B:751-763.
32. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-277.
33. Vis JC, Nicholson LF, Faull RL, Evans WH, Severs NJ, Green CR. Connexin expression in Huntington's diseased human brain. Cell Biol Int 1998;22(11-12):837-847.
34. Politis M, Pavese N, Tai YF, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp 2011;32:258-270.
35. van den Bogaard SJ, Dumas EM, Acharya TP, et al. Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J Neurol 2011;258:412-420.
36. Allen KL, Waldvogel HJ, Glass M, Faull RL. Cannabinoid (CB[1]), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat 2009;37:266-281.
37. Rostrup E, Knudsen GM, Law I, Holm S, Larsson HB, Paulson OB. The relationship between cerebral blood flow and volume in humans. Neuroimage 2005;24:1-11.
38. Hua J, Stevens RD, Huang AJ, Pekar JJ, van Zijl PC. Physiological origin for the BOLD poststimulus undershoot in human brain: vascular compliance versus oxygen metabolism. J Cereb Blood Flow Metab 2011;31:1599-1611.
39. Niatsetskaya Z, Basso M, Speer RE, et al. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal 2010;12:435-443.
40. Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008;9:169-181.